AlphaTON Capital Corp. Common Stock (ATON)

• Market cap: $13.4M
• 1 day: 15.72%
• 5 days: -18.76%
• 1 month: -36.67%
• 3 months: -22.5%
• 6 months: 47.25%
• Year to date: 20.7%
• 1 year: 107.39%
• 5 years: -99.2%
• 10 years: -99.2%
• Sector: Healthcare
• Industry: Biotechnology

About: AlphaTON Capital Corp is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Employees: 4

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.81% less ownership

Funds ownership: 2.76% [Q1] → 1.95% (-0.81%) [Q2]

7% less funds holding

Funds holding: 15 [Q1] → 14 (-1) [Q2]

61% less capital invested

Capital invested by funds: $286K [Q1] → $112K (-$174K) [Q2]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4